Who is sponsoring NCT02674412?

NCT02674412 is sponsored by The Cleveland Clinic.

What condition does NCT02674412 study?

NCT02674412 studies Functional Dysphagia, Ineffective Esophageal Motility.

What drugs are being tested in NCT02674412?

Interventions: Buspirone, Placebo.

What is the status of NCT02674412?

NCT02674412 is currently COMPLETED.

Last reviewed 2018-07-10 · How we verify

Placebo-controlled, Randomized, Double-blind, Cross-over Style Trial of Buspirone in Functional Dysphagia

NCT02674412 NA COMPLETED Results posted

This study evaluates the utility of buspirone in patients who have a diagnosis of functional dysphagia. All participants will be randomized to receive either a placebo pill or buspirone. Subsequently, we will evaluate whether their swallowing is improved. Participants who were randomized to receive placebo will then receive buspirone and those who were receiving buspirone will receive placebo. We will again evaluate whether their swallowing improved.

Details

Lead sponsor	The Cleveland Clinic
Phase	NA
Status	COMPLETED
Enrolment	10
Start date	2016-02
Completion	2017-04-12

Conditions

Functional Dysphagia
Ineffective Esophageal Motility

Interventions

Buspirone
Placebo

Primary outcomes

Change in Distal Contractile Index (DCI) on High Resolution Esophageal Manometry — Change in the score from Baseline to 14 days
DCI is a measure of the strength of muscle contractions in the esophagus while swallowing. It is measured in mm Hg, and values greater than 450mm Hg are considered Normal.